iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 654 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Why I Work to Bridge the Gap Between People With Cancer... May 27, 2021 Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected... September 30, 2025 Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2... May 8, 2021 FDA Warns That Robotic Surgery May Lower Life Expectancy for Breast... March 1, 2019 Load more HOT NEWS Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam,... Self Destruction Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated... FDA Approves Crizotinib for Children and Young Adults with Relapsed or...
